Long-term management of deep vein thrombosis

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A venous thromboembolic event may cause substantial long-term morbidity despite the best available treatment. Venous thromboembolism (VTE) recurs in approximately 30% of patients within eight years of the acute event, and a similar proportion develop post-thrombotic syndrome, imposing a notable clinical and financial burden. Conventional treatment of VTE comprises an initial 5-10 day course of intravenous unfractionated heparin (UFH), followed by oral anticoagulants for 3-6 months. Thrombolytic therapy, vena caval filters and surgical thrombectomy are reserved for patients with complications. Alternative approaches, including more intensive initial anticoagulation or extended secondary prevention, may improve long-term outcomes. Low-molecular-weight heparins (LMWHs) are at least as effective as UFH in acute therapy and are suitable for home treatment, offering the potential for cost reductions and improved patient convenience. Consequently, LMWHs are replacing UFH in initial treatment of VTE. The optimal duration of secondary VTE prophylaxis remains uncertain. Extended therapy with LMWH reduces the frequency of VTE recurrence, but routine use of prolonged therapy is not economically viable. Targeting extended therapy to patients at greatest risk of recurrence, for example, patients with identified congenital thrombophilia, would maximize cost-effectiveness. Comprehensive risk assessment models are now needed to stratify patients for primary VTE risk level, allowing appropriate targeting of prophylaxis, more intensive initial treatment or extended therapy for acute VTE.

Original languageEnglish
JournalBlood Coagulation and Fibrinolysis
Volume10
Issue number6 SUPPL. 2
Publication statusPublished - 1999

Fingerprint

Venous Thrombosis
Venous Thromboembolism
Low Molecular Weight Heparin
Therapeutics
Heparin
Recurrence
Thrombectomy
Venae Cavae
Thrombophilia
Thrombolytic Therapy
Secondary Prevention
Anticoagulants
Cost-Benefit Analysis
Morbidity
Costs and Cost Analysis

Keywords

  • Home therapy
  • Initial treatment
  • Low-molecular-weight heparins
  • Oral anticoagulants
  • Risk assessment
  • Secondary prophylaxis
  • Unfractionated heparin
  • Venous thromboembolism

ASJC Scopus subject areas

  • Hematology

Cite this

Long-term management of deep vein thrombosis. / Piovella, F.; Barone, M.

In: Blood Coagulation and Fibrinolysis, Vol. 10, No. 6 SUPPL. 2, 1999.

Research output: Contribution to journalArticle

@article{380b7ac445ba4c5d81b60c02e55ee016,
title = "Long-term management of deep vein thrombosis",
abstract = "A venous thromboembolic event may cause substantial long-term morbidity despite the best available treatment. Venous thromboembolism (VTE) recurs in approximately 30{\%} of patients within eight years of the acute event, and a similar proportion develop post-thrombotic syndrome, imposing a notable clinical and financial burden. Conventional treatment of VTE comprises an initial 5-10 day course of intravenous unfractionated heparin (UFH), followed by oral anticoagulants for 3-6 months. Thrombolytic therapy, vena caval filters and surgical thrombectomy are reserved for patients with complications. Alternative approaches, including more intensive initial anticoagulation or extended secondary prevention, may improve long-term outcomes. Low-molecular-weight heparins (LMWHs) are at least as effective as UFH in acute therapy and are suitable for home treatment, offering the potential for cost reductions and improved patient convenience. Consequently, LMWHs are replacing UFH in initial treatment of VTE. The optimal duration of secondary VTE prophylaxis remains uncertain. Extended therapy with LMWH reduces the frequency of VTE recurrence, but routine use of prolonged therapy is not economically viable. Targeting extended therapy to patients at greatest risk of recurrence, for example, patients with identified congenital thrombophilia, would maximize cost-effectiveness. Comprehensive risk assessment models are now needed to stratify patients for primary VTE risk level, allowing appropriate targeting of prophylaxis, more intensive initial treatment or extended therapy for acute VTE.",
keywords = "Home therapy, Initial treatment, Low-molecular-weight heparins, Oral anticoagulants, Risk assessment, Secondary prophylaxis, Unfractionated heparin, Venous thromboembolism",
author = "F. Piovella and M. Barone",
year = "1999",
language = "English",
volume = "10",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "6 SUPPL. 2",

}

TY - JOUR

T1 - Long-term management of deep vein thrombosis

AU - Piovella, F.

AU - Barone, M.

PY - 1999

Y1 - 1999

N2 - A venous thromboembolic event may cause substantial long-term morbidity despite the best available treatment. Venous thromboembolism (VTE) recurs in approximately 30% of patients within eight years of the acute event, and a similar proportion develop post-thrombotic syndrome, imposing a notable clinical and financial burden. Conventional treatment of VTE comprises an initial 5-10 day course of intravenous unfractionated heparin (UFH), followed by oral anticoagulants for 3-6 months. Thrombolytic therapy, vena caval filters and surgical thrombectomy are reserved for patients with complications. Alternative approaches, including more intensive initial anticoagulation or extended secondary prevention, may improve long-term outcomes. Low-molecular-weight heparins (LMWHs) are at least as effective as UFH in acute therapy and are suitable for home treatment, offering the potential for cost reductions and improved patient convenience. Consequently, LMWHs are replacing UFH in initial treatment of VTE. The optimal duration of secondary VTE prophylaxis remains uncertain. Extended therapy with LMWH reduces the frequency of VTE recurrence, but routine use of prolonged therapy is not economically viable. Targeting extended therapy to patients at greatest risk of recurrence, for example, patients with identified congenital thrombophilia, would maximize cost-effectiveness. Comprehensive risk assessment models are now needed to stratify patients for primary VTE risk level, allowing appropriate targeting of prophylaxis, more intensive initial treatment or extended therapy for acute VTE.

AB - A venous thromboembolic event may cause substantial long-term morbidity despite the best available treatment. Venous thromboembolism (VTE) recurs in approximately 30% of patients within eight years of the acute event, and a similar proportion develop post-thrombotic syndrome, imposing a notable clinical and financial burden. Conventional treatment of VTE comprises an initial 5-10 day course of intravenous unfractionated heparin (UFH), followed by oral anticoagulants for 3-6 months. Thrombolytic therapy, vena caval filters and surgical thrombectomy are reserved for patients with complications. Alternative approaches, including more intensive initial anticoagulation or extended secondary prevention, may improve long-term outcomes. Low-molecular-weight heparins (LMWHs) are at least as effective as UFH in acute therapy and are suitable for home treatment, offering the potential for cost reductions and improved patient convenience. Consequently, LMWHs are replacing UFH in initial treatment of VTE. The optimal duration of secondary VTE prophylaxis remains uncertain. Extended therapy with LMWH reduces the frequency of VTE recurrence, but routine use of prolonged therapy is not economically viable. Targeting extended therapy to patients at greatest risk of recurrence, for example, patients with identified congenital thrombophilia, would maximize cost-effectiveness. Comprehensive risk assessment models are now needed to stratify patients for primary VTE risk level, allowing appropriate targeting of prophylaxis, more intensive initial treatment or extended therapy for acute VTE.

KW - Home therapy

KW - Initial treatment

KW - Low-molecular-weight heparins

KW - Oral anticoagulants

KW - Risk assessment

KW - Secondary prophylaxis

KW - Unfractionated heparin

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=0032834633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032834633&partnerID=8YFLogxK

M3 - Article

VL - 10

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 6 SUPPL. 2

ER -